General Biological, founded in 2023, operates a biomanufacturing platform that converts agricultural feedstock into industrial chemicals at scale, with an initial focus on specialty C4 molecules including tetrahydrofuran (THF) and N-methyl-2-pyrrolidone (NMP) for use in battery electrolytes, semiconductors, pharmaceuticals, and adhesives. The company operates a 37-acre production facility on the Mississippi River in Northeast Louisiana with 1.7 million liters of fermentation capacity and 15,000+ tons per year of bio-based chemical production capacity. General Biological's technology replaces traditional fermentation organisms with a proprietary microorganism selected for industrial scalability and contamination resistance, enabling the use of smaller, modular plastic bioreactors instead of expensive steel vessels. The company was co-founded by Abhi Godavarthi (CEO) and David Sozanski (CTO), both with backgrounds in bioengineering and systems design. General Biological has received funding from A* Capital and Lowercarbon Capital, though specific round amounts and dates are not publicly detailed in available sources.